DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Celexa (Citalopram Hydrobromide) - Published Studies

 
 



Celexa Related Published Studies

Well-designed clinical trials related to Celexa (Citalopram)

Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. [2015]

Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial. [2014]

A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. [2014]

Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials. [2014]

Effects of escitalopram on markers of bone turnover: a randomized clinical trial. [2014]

Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects. [2014]

Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. [2012]

Effect of escitalopram on hot flash interference: a randomized, controlled trial. [2012]

Citalopram for agitation in Alzheimer's disease: design and methods. [2012]

No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression. [2012]

Effects of reboxetine and citalopram on appraisal of infant facial expressions and attentional biases. [2012]

Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. [2012]

Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. [2011.11]

A review of escitalopram and citalopram in child and adolescent depression. [2011.11]

Escitalopram for the treatment of major depressive disorder in youth. [2011.10]

Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. [2011.10]

Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study. [2011.09]

The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. [2011.07]

Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. [2011.07]

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]

Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. [2011.06.15]

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. [2011.06]

Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. [2011.05.01]

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. [2011.05]

A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. [2011.04.30]

Influence of citalopram and environmental temperature on exercise-induced changes in BDNF. [2011.04.25]

Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. [2011.04.15]

Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. [2011.04]

Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. [2011.04]

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. [2011.03.01]

Efficacy of escitalopram compared to citalopram: a meta-analysis. [2011.03]

Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. [2011.02]

Citalopram reduces endotoxin-induced fatigue. [2011.02]

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. [2011.01.19]

Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? [2011.01.14]

Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? [2011.01]

Escitalopram for the treatment of major depressive disorder in youth. [2011]

Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels. [2011]

Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. [2011]

A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. [2011]

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. [2010.12]

Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. [2010.12]

Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. [2010.11]

[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. [2010.10]

Efficacy of escitalopram compared to citalopram: a meta-analysis. [2010.09.29]

Comparative bioavailability of two escitalopram formulations in healthy human volunteers. [2010.08]

Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. [2010.08]

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. [2010.07.10]

Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. [2010.07]

Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. [2010.07]

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. [2010.07]

Escitalopram attenuates posterior cingulate activity during self-evaluation in healthy volunteers. [2010.05.30]

Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. [2010.05]

Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine. [2010.05]

MRP1 polymorphisms associated with citalopram response in patients with major depression. [2010.04]

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. [2010.03]

Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. [2010.03]

Acute citalopram administration may disrupt contextual information processing in healthy males. [2010.03]

Escitalopram and enhancement of cognitive recovery following stroke. [2010.02]

Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. [2010.02]

Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. [2010.02]

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. [2010.01.25]

Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. [2010.01.15]

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. [2010.01]

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. [2010.01]

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. [2010.01]

Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. [2010]

Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. [2010]

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. [2010]

Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. [2009.12]

Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. [2009.12]

Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. [2009.11]

Specific effects of escitalopram on neuroendocrine response. [2009.11]

Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. [2009.10.15]

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. [2009.09.30]

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. [2009.09]

Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. [2009.09]

Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. [2009.08.11]

Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. [2009.08]

Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. [2009.07]

Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. [2009.07]

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. [2009.07]

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. [2009.06]

Effect of a single dose of citalopram on amygdala response to emotional faces. [2009.06]

A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. [2009.05]

Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). [2009.04.07]

Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. [2009.04]

Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. [2009.04]

Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. [2009.03]

A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). [2009.03]

The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. [2009.03]

Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study. [2009.03]

A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). [2009.02.03]

Citalopram intervention for hostility: results of a randomized clinical trial. [2009.02]

Escitalopram: an open-label study of bereavement-related depression and grief. [2009.02]

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. [2009.01.21]

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. [2009]

Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial. [2008.12.23]

No effect of six weeks of treatment with escitalopram on mood in healthy volunteers--irrespective of genotype for the promoter of the serotonin transporter. [2008.12.15]

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. [2008.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017